GlassScriptPhysician profile
Ashley Roden
NPI 1033809637
$1,997.60
in general payments reported to CMS, 2019-2025
20 companies · $1,673 in 2025
The $1,673 reported for 2025 was more than what 90% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $14.66 · 2024: $310 · 2025: $1,673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,998.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,997.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $477.56 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $261.22 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Lundbeck LLC | $222.65 | 2024-2025 | Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $194.42 | 2024-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $137.38 | 2024-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $90.38 | 2024-2025 | Ingrezza |
| Alkermes, INC. | $82.25 | 2024-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $64.48 | 2024-2025 | Austedo Xr, Austedo Xr |
| Almatica Pharma LLC | $64.46 | 2025 | Loreev Xr |
| Lilly USA, LLC | $51.06 | 2025 | Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $48.39 | 2025 | Trintellix |
| Neos Therapeutics, LP | $47.83 | 2025 | Adzenys Xr-Odt, Exxua |
| Tris Pharma INC | $42.56 | 2023-2025 | Dyanavel Xr |
| Corium, LLC | $41.95 | 2024-2025 | Azstarys |
| Axsome Therapeutics, INC. | $37.06 | 2025 | Auvelity |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $36.97 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $34.59 | 2025 | Qelbree |
| Janssen Pharmaceuticals, INC | $29.17 | 2025 | Spravato |
| Novo Nordisk INC | $19.47 | 2025 | Wegovy |
| Biogen, INC. | $13.75 | 2025 | Zurzuvae |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Roden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.